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NeurotoxicityAbstract In the present study, a series of novel 2-(substituted benzylidene)-7-(4-chlorophenyl)-
5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one derivatives (4a–i) were designed and synthesized
to meet the structural requirements essential for antiepileptic activity. Antiepileptic screening was
performed by maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) seizures
tests and neurotoxicity was determined by the rotorod test. Among the synthesized compounds 4f,
4g and 4h were found active in both MES and scPTZ models. In the view of results the most active
compounds carry ﬂuoro> chloro> bromo substituent’s at the para position in the phenyl ring. The
chemical structures of the synthesized compounds were conﬁrmed by means of IR, 1H NMR, mass
spectroscopy and elemental analysis.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is one of the most common brain disorders character-
ized by paroxysmal, excessive, and hypersynchronousdischarges of a large number of neurons (McNamara, 1999).
Epilepsy affects approximately 1% of the global population
and most frequent neurologic affection characterized by exces-
sive temporary neuronal discharge (McNamara, 2001). Several
newer antiepileptic drugs (such as pregabalin, stiripentol,
zonisamide, tiagabine, lamotrigine, levetiracetam, topiramate)
are greatly compromised by severe side effects such as vertigo,
ataxia, headache, hirsutism, hepatotoxicity, gastrointestinal
and cardiovascular side effects. Moreover about 30% of
patients have uncontrolled seizures (McNamara et al., 2006;
Kwan and Brodie, 2000; Spear, 2001). The insufﬁcient
S2 V. Karthick et al.information on the cellular mechanism of epilepsy in humans
and the complex mechanism of action of most of the antiepilep-
tic drugs makes it difﬁcult to use rational methodologies in the
ﬁeld of drug discovery. There is a substantial need for the devel-
opment of new, more effective and less toxic antiepileptic drugs
(Smith et al., 2007). The literature survey revealed that the
important core fragments are deﬁned by presence of a hydrogen
bonding site (HBS), one electron donor atom, (D) and a hydro-
phobic domain (A) (aryl ring substituted/unsubstituted)
(Bruno-Blanch et al., 2003; Estrada and Pena, 2000). These core
fragments were found in the structures of well-established anti-
epileptics such as carbamazepine, phenytoin or mephenytoin,
newest and clinical trial drugs e.g. retigabine, AWD 131 (Fig
1). Therefore, continued search for novel antiepileptic drugsCl N
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Figure 1 Comparison of the pharmacophoric features of known ant
structural features: (A) hydrophobic ring system, (HBS) hydrogen bowith less toxicity and more selectivity continues to be an area
of investigation in the ﬁeld of medicinal chemistry. Many stud-
ies revealed that the pyrimidine ring is an important lead moiety
in the ﬁeld of agriculture, microbiology and medicine which
exhibits a wide spectrum of biological activities such as antiep-
ileptic (Francis et al., 1991; Ashalatha et al., 2007), anticancer
(Abou El Ella et al., 2008; Nguyen, 2008), antiviral (Renau
et al., 1996), antibacterial (Kuyper et al., 1996), antioxidant
(Andrus et al., 1997; Bundy et al., 1975) and anxiolytic (Meada
et al., 1998) activities. These exciting manifold activities of
pyrimidine derivatives stimulated us to synthesize a series of
2-(substituted benzylidene)-7-(4-chlorophenyl)-5-(furan-2-yl)-
2H-thiazolo[3,2-a]pyrimidin-3(7H)-one derivatives for their
potential antiepileptic properties (Scheme 1).O
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Scheme 1 Synthetic protocols of target compounds (4a–i).
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2.1. Materials
The chemicals and reagents used were obtained from various
chemical units Aldrich Co., E. Merck India Ltd., CDH, and
SD Fine Chem. These solvents used were of LR grade and
puriﬁed before their use. The silica gel G used for analytical
chromatography (TLC) was obtained from E. Merck India
Ltd. Melting points were measured in open capillary tubes on
a Boetius apparatus and are uncorrected. 1H NMR spectra
were taken on a Bruker ultra shield (400 MHz) NMR spec-
trometer in (DMSO-d6) using tetramethylsilane [(CH3)4Si] as
the internal standard. Chemical shift (d) is expressed in ppm.
Mass spectra were obtained on a JEOL-SX-102 instrument
using electron impact ionization. All the IR spectra were
recorded in KBr pellets on a Jasco FT-IR 410 spectrometer.
Elemental analyses were performed on a Perkin Elmer model
240c analyzer and were within ±0.4% of the theoretical values.
2.2. Methods
2.2.1. General procedure for the synthesis of title compounds
(4a–i)
The key intermediates were synthesized by a previously
reported method (El-Baih et al., 2006). 3-(4-Chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one 1 was prepared by stirring the
mixture of KOH (3.1 g), water (20 mL), ethanol (15 mL),
2-acetyl furan (4.7 g) and the 4-chloro aldehyde (6.0 g) at 30–
40 C for 2 h and kept overnight. It was then ﬁltered, washed
with water and with ethanol, dried and reﬂuxed with glacial
acetic acid (10 mL) for 2 h. The crystals that separated after
cooling were ﬁltered and washed with water, dried and used
for further reaction. Yield 72%, mp 202 C; IR (KBr) cm1:
2996 (Ar-CHstr), 1732 (C‚O), 1522 (C‚C), 1030 (Cyclic
C–O–Cstr), 726 (C–Cl);
1H NMR (400 MHz, d ppm): 7.28
(dd, J1 = 7.7 Hz, J2 = 1.83 Hz 2H, ArH), 7.56 (d,
J= 8.2 Hz, 2H, ArH), 6.52–7.02 (m, 3H, –CH-Furan), 6.14
(d, 2H,=CH); MS (EI) m/z 234 [M+2]; Anal. Calculated
for C13H9ClO2: C, 67.11; H, 3.90; Found: C, 67.16; H, 3.96.
A mixture of 3-(4-Chlorophenyl)-1-(furan-2-yl)prop-2-
en-1-one 1 (0.039 mol) thiourea (2.3 g) and KOH (2.5 g) in eth-
anol (100 mL) was reﬂuxed for 3 h. The reaction mixture was
concentrated to half of its volume, diluted with water, then acid-
iﬁed with dilute acetic acid and kept overnight. The solid thus
obtained, was ﬁltered, washed with water and recrystallized
from ethanol to give 4-(4-chlorophenyl)-6-(furan-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione (2). Yield 66%, mp 224 C;
IR (KBr) cm1: 3364 (NHstr), 3018 (Ar-CHstr), 1629 (C‚C),
1038 (Cyclic C–O–Cstr), 714 (C-Cl);
1H NMR (400 MHz, d
ppm): 7.42 (dd, J1 = 6.4 Hz, J2 = 1.8 Hz 2H, ArH), 7.40 (d,
J= 8.2 Hz, 2H, ArH), 6.63–6.92 (m, 3H, –CH-furan), 6.12
(dd, J1 = 8.4 Hz, J2 = 2.0 Hz 1H, pyrimidine H), 4.67 (dd,
J1 = 12.0 Hz, J2 = 2.0 Hz 1H, pyrimidine H), 3.12 (s, 2H,
–NH); MS (EI) m/z 292 [M+2]; Anal. Calculated for
C14H11ClN2OS: C, 57.83; H, 3.81; N, 9.63; Found: C, 57.89;
H, 3.87; N, 9.67.
Chloroacetic acid (9.0 g) was melted in a water bath and 2
(0.009 mol) added to it portionwise to maintain its homogene-
ity. The homogeneous mixture was further heated in a water
bath for 30 min and kept overnight. The solid thus obtained
was washed with water and recrystallized from ethanol to give
7-(4-chlorophenyl)-5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-
3(7H)-one (3). Yield 66%, mp 268 C; IR (KBr) cm1: 3352
(NHstr), 3041 (Ar-CHstr), 1641 (C‚O), 1514 (C‚C), 1026
(Cyclic C–O–Cstr), 742 (C–Cl);
1H NMR (400 MHz, d ppm):
7.38 (dd, J1 = 7.1 Hz, J2 = 2.2 Hz 2H, ArH), 7.70 (d,
J= 7.9 Hz, 2H, ArH), 6.73–7.06 (m, 3H, –CH-furan), 5.42
(dd, J1 = 7.5 Hz, J2 = 2.1 Hz 1H, pyrimidine H), 4.17 (dd,
J1 = 12.1 Hz, J2 = 1.8 Hz 1H, pyrimidine H), 3.62 (s, 2H,
–CH2 thiazole); MS (EI) m/z 332 [M+2]; Anal. Calcd for
C16H11ClN2O2S: C, 58.09; H, 3.35; N, 8.47; Found: C,
58.12; H, 3.39; N, 8.49.
A mixture of 3 (0.002 mol), substituted benzaldehyde
(0.002 mol) and anhydrous CH3COONa (0.002 mol) in 100%
glacial acetic acid (10 mL) was reﬂuxed for 4 h. The reaction
mixture was kept overnight and the solid, thus separated,
was ﬁltered, washed with water and recrystallized from ethanol
to furnish 2-(substituted benzylidene)-7-(4-chlorophenyl)-
5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4a-i).
2.2.2. 2-benzylidene-7-(4-chlorophenyl)-5-(furan-2-yl)-
2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4a)
Yield 71%, mp 281 C; IR (KBr) cm1: 3064 (Ar-CHstr), 1647
(C‚O), 1519 (C‚C benzylidine), 1031 (Cyclic C–O–Cstr), 719
(C–Cl); 1H NMR (400 MHz, d ppm): 7.46 (dd, J1 = 7.3 Hz,
J2 = 1.8 Hz 2H, ArH), 7.52 (d, J= 6.2 Hz, 2H, ArH), 7.56–
7.84 (m, 5H, Ar-H), 7.09 (s, 1H, –CH benzylidine) 6.53–6.92
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pyrimidine H), 3.29 (dd, J1 = 17.6 Hz, J2 = 1.8 Hz 1H,
pyrimidine H); MS (EI) m/z 420 [M+2]; Anal. Calculated
for C23H15ClN2O2S: C, 65.95; H, 3.61; N, 6.69; Found: C,
65.91; H, 3.67; N, 6.64.
2.2.3. 2-(3,4,5-trimethoxybenzylidene)-7-(4-chlorophenyl)-
5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4b)
Yield 77%, mp 299 C; IR (KBr) cm1: 3034 (Ar-CHstr), 1621
(C‚O), 1512 (C‚C), 1034 (Cyclic C–O–Cstr), 711 (C–Cl);
1H
NMR (400 MHz, d ppm): 7.12 (dd, J1 = 6.8 Hz, J2 = 1.5 Hz
2H, ArH), 7.37 (d, J= 7.3 Hz, 2H, ArH), 7.52–7.71 (m, 2H,
Ar-H), 7.02 (s, 1H, –CH Benzylidine) 6.26–6.54 (m, 3H,
–CH-Furan), 5.17 (dd, J1 = 8.3 Hz, J2 = 2.5 Hz 1H, pyrimi-
dine H), 3.14 (dd, J1 = 17.2 Hz, J2 = 1.3 Hz 1H, pyrimidine
H), 3.64 (m, 9H, –(OCH3)3); MS (EI) m/z 510 [M+2]; Anal.
Calculated for C26H21ClN2O5S: C, 61.35; H, 4.16; N, 5.50;
Found: C, 61.37; H, 4.11; N, 5.52.
2.2.4. 2-(3,4-dimethylbenzylidene)-7-(4-chlorophenyl)-
5-(furan-2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4c)
Yield 72%, mp 279 C; IR (KBr) cm1: 3042 (Ar-CHstr), 1627
(C‚O), 1529 (C‚C), 1029 (Cyclic C–O–Cstr), 731 (C–Cl);
1H
NMR (400 MHz, d ppm): 7.27 (dd, J1 = 6.3 Hz, J2 = 1.8 Hz
2H, ArH), 7.44 (d, J= 7.2 Hz, 2H, ArH), 7.59–7.76 (m, 3H,
Ar-H), 7.06 (s, 1H, –CH Benzylidine) 6.12–6.62 (m, 3H,
–CH-Furan), 5.19 (dd, J1 = 8.7 Hz, J2 = 2.1 Hz 1H, pyrimi-
dine H), 3.18 (dd, J1 = 17.7 Hz, J2 = 1.6 Hz 1H, pyrimidine
H), 2.79 (m, 6H, –(CH3)2); MS (EI) m/z 448 [M+2]; Anal.
Calcd for C25H19ClN2O2S: C, 67.18; H, 4.28; N, 6.27; Found:
C, 67.22; H, 4.31; N, 6.29.
2.2.5. 2-(4-methoxybenzylidene)-7-(4-chlorophenyl)-5-(furan-
2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4d)
Yield 81%, mp 272 C; IR (KBr) cm1: 3047 (Ar-CHstr), 1621
(C‚O), 1532 (C‚C), 1027 (Cyclic C–O–Cstr), 716 (C–Cl);
1H
NMR (400 MHz, d ppm): 7.34 (dd, J1 = 6.1 Hz, J2 = 1.3 Hz
2H, ArH), 7.48 (d, J= 7.6 Hz, 2H, ArH), 7.45–7.66 (m, 4H,
Ar-H), 7.04 (s, 1H, –CH Benzylidine) 6.24–6.69 (m, 3H,
–CH-Furan), 5.24 (dd, J1 = 8.3 Hz, J2 = 2.7 Hz 1H, pyrimi-
dine H), 3.12 (dd, J1 = 17.1 Hz, J2 = 1.2 Hz 1H, pyrimidine
H), 2.97 (s, 3H, –OCH3); MS (EI) m/z 450 [M+2]; Anal.
Calculated for C24H17ClN2O3S: C, 64.21; H, 3.82; N, 6.24;
Found: C, 64.26; H, 3.85; N, 6.27.
2.2.6. 2-(4-methylbenzylidene)-7-(4-chlorophenyl)-5-(furan-
2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4e)
Yield 76%, mp 289 C; IR (KBr) cm1: 3052 (Ar-CHstr), 1636
(C‚O), 1539 (C‚C), 1034 (Cyclic C–O–Cstr), 709 (C–Cl);
1H
NMR (400 MHz, d ppm): 7.39 (dd, J1 = 7.2 Hz, J2 = 1.8 Hz
2H, ArH), 7.51 (d, J= 7.7 Hz, 2H, ArH), 7.62–7.74 (m, 4H,
Ar-H), 7.06 (s, 1H, –CH benzylidine) 6.25–6.72 (m, 3H,
–CH-furan), 5.42 (dd, J1 = 8.1 Hz, J2 = 1.7 Hz 1H, pyrimi-
dine H), 3.11 (dd, J1 = 13.2 Hz, J2 = 2.2 Hz 1H, pyrimidine
H), 2.21 (s, 3H, –CH3); MS (EI) m/z 434 [M+2]; Anal. Calcu-
lated for C24H17ClN2O2S: C, 66.58; H, 3.96; N, 6.47; Found:
C, 66.55; H, 3.97; N, 6.42.
2.2.7. 2-(4-ﬂuoro benzylidene)-7-(4-chlorophenyl)-5-(furan-
2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4f)
Yield 71%, mp 281 C; IR (KBr) cm1: 3059 (Ar-CHstr), 1631
(C‚O), 1533 (C‚C), 1033 (Cyclic C–O–Cstr), 742 (C–Cl),1112 (C-F); 1H NMR (400 MHz, d ppm): 7.42 (dd,
J1 = 6.8 Hz, J2 = 1.4 Hz 2H, ArH), 7.57 (d, J= 7.0 Hz, 2H,
ArH), 7.62–7.91 (m, 4H, Ar-H), 7.09 (s, 1H, –CH benzylidine)
6.21–6.74 (m, 3H, –CH-furan), 5.47 (dd, J1 = 7.6 Hz, J2 =
1.2 Hz 1H, pyrimidine H), 3.17 (dd, J1 = 12.5 Hz, J2 =
2.4 Hz 1H, pyrimidine H); MS (EI) m/z 438 [M+2]; Anal. Cal-
culated for C23H14ClFN2O2S: C, 63.23; H, 3.23; N, 6.41;
Found: C, 63.21; H, 3.24; N, 6.45.
2.2.8. 2-(4-chlorobenzylidene)-7-(4-chlorophenyl)-5-(furan-
2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4g)
Yield 82%, mp 294 C; IR (KBr) cm1: 3051 (Ar-CHstr), 1639
(C‚O), 1537 (C‚C), 1037 (Cyclic C–O–Cstr), 734 (C–Cl);
1H
NMR (400 MHz, d ppm): 7.44 (dd, J1 = 7.1 Hz, J2 = 1.8 Hz
2H, ArH), 7.53 (d, J= 6.8 Hz, 2H, ArH), 7.69–7.96 (m, 4H,
Ar-H), 7.01 (s, 1H, –CH benzylidine) 6.22–6.71 (m, 3H,
–CH-furan), 5.49 (dd, J1 = 7.9 Hz, J2 = 1.8 Hz 1H, pyrimi-
dine H), 3.14 (dd, J1 = 14.2 Hz, J2 = 2.0 Hz 1H, pyrimidine
H); MS (EI) m/z 455 [M+2], 457 [M+4]; Anal. Calcd for
C23H14Cl2N2O2S: C, 60.94; H, 3.11; N, 6.18; Found: C,
60.91; H, 3.14; N, 6.21.
2.2.9. 2-(4-bromobenzylidene)-7-(4-chlorophenyl)-5-(furan-2-
yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4h)
Yield 72%, mp 281 C; IR (KBr) cm1: 3054 (Ar-CHstr), 1642
(C‚O), 1541 (C‚C), 1042 (Cyclic C–O–Cstr), 741 (C–Cl), 627
(C-Br); 1H NMR (400 MHz, d ppm): 7.46 (dd, J1 = 7.9 Hz,
J2 = 2.0 Hz 2H, ArH), 7.54 (d, J= 6.3 Hz, 2H, ArH), 7.66–
7.91 (m, 4H, Ar-H), 7.07 (s, 1H, –CH benzylidine) 6.26–6.73
(m, 3H, –CH-furan), 5.41 (dd, J1 = 8.2 Hz, J2 = 2.0 Hz 1H,
pyrimidine H), 3.07 (dd, J1 = 16.1 Hz, J2 = 2.2 Hz 1H,
pyrimidine H); MS (EI) m/z 499 [M+2], 501 [M+4]; Anal.
Calculated for C23H14BrClN2O2S: C, 55.49; H, 2.83; N, 5.63;
Found: C, 55.45; H, 2.84; N, 5.66.
2.2.10. 2-(4-nitrobenzylidene)-7-(4-chlorophenyl)-5-(furan-
2-yl)-2H-thiazolo[3,2-a]pyrimidin-3(7H)-one (4i)
Yield 79%, mp 283 C; IR (KBr) cm1: 3056 (Ar-CHstr), 1648
(C‚O), 1545 (C‚C), 1045 (Cyclic C–O–Cstr), 732 (C-Cl);
1H
NMR (400 MHz, d ppm): 7.86 (dd, J1 = 8.0 Hz, J2 = 2.0 Hz
2H, ArH), 7.92 (d, J= 6.3 Hz, 2H, ArH), 8.12–8.35 (m, 4H,
Ar-H), 7.03 (s, 1H, –CH benzylidine) 6.16–6.52 (m, 3H,
–CH-furan), 5.43 (dd, J1 = 8.2 Hz, J2 = 2.2 Hz 1H, pyrimidine
H), 3.12 (dd, J1 = 12.4 Hz, J2 = 1.8 Hz 1H, pyrimidineH);MS
(EI) m/z 465 [M+2]; Anal. Calculated for C23H14ClN3O4S: C,
59.55; H, 3.04; N, 9.06; Found: C, 59.51; H, 3.07; N, 9.09.
2.3. Pharmacology
2.3.1. The maximal electroshock test (MES)
The MES is a model for generalized tonic-clonic seizures and
provides a hint of a compound’s ability to stop seizure spread
when all the neuronal circuits in the brain are maximally active.
These seizures are extremely reproducible and are electro phys-
iologically reliable with human seizures. For theMES, a drop of
anesthetic and electrolyte solution (tetracaine hydrochloride
(0.5%) in saline (0.9%)) was applied to the eyes of individual
animals before the placement of the corneal electrodes. The
electrical stimulus in the MES test was 50 milli Ampere,
60 Hz, for mice delivered for 0.2 s by an apparatus similar to
that initially described by Woodbury and Davenport (Wood-
bury and Davenport, 1952; White et al., 1995). Abolition of
Table 1 Antiepileptic activity and neurotoxicity of com-
pounds (4a–i) administered intraperitoneally to mice.
Compound MESa screening scPTZb screening NTc screening
0.5 hd 4.0 hd 0.5 hd 4.0 hd 0.5 hd 4.0 hd
4a 100 300 100 300 300 300
4b 300 – 300 – ND ND
4c 300 – 300 – ND ND
4d 100 300 100 300 100 –
4e 100 300 100 300 300 –
4f 30 100 30 100 300 –
4g 30 100 100 100 300 300
4h 30 100 100 300 300 300
4i 300 – – 300 ND ND
Phenytoine 30 30 – – 100 100
Ethosuximidef – – 30 100 – –
The sign – (mdash) represents an absence of activity at the maxi-
mum dose administered (300 mg/kg).
ND - Not determined.
a Maximal electroshock test (administered intraperitoneally to
mice at doses ranging from 30 to 300 mg/kg).
b Subcutaneous pentylenetetrazole test (administered intraperi-
toneally to mice at doses ranging from 30 to 300 mg/kg).
c Neurotoxicity (administered intraperitoneally to mice at doses
ranging from 30 to 300 mg/kg).
d Time of test after drug administration.
e Reference drug, data for phenytoin ref (Yogeeswari et al., 2005).
f Reference drug, data for ethosuximide ref (Rajak et al., 2009).
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the endpoint. Mice are initially tested with different doses of 30,
100 and 300 mg/kg of the test compound given by i.p. injection
at various intervals.
2.3.2. The subcutaneous pentylenetetrazole seizure test (scPTZ)
Subcutaneous injection of the convulsant Pentylenetetrazole
produces clonic seizures in laboratory animals. The scPTZ test
detects the ability of test compounds to raise the seizure
threshold of an animal and thus protect it from exhibiting a
clonic seizure. Animals are pretreated with various doses of
the test compound given by i.p. injection. The dose of Penty-
lenetetrazole which induces convulsions in 97% of animals
(CD97: 85 mg/kg mice) is injected into a loose fold of the skin
in the midline of the neck. The animals are placed in isolation
cages to minimize stress (Swinyard et al., 1961) and observed
for the next 30 min for the presence or absence of a seizure.
An episode of clonic spasms, approximately 3–5 s, of the fore
and/or hindlimbs, jaws, or vibrissae is taken as the endpoint.
Animals which do not meet this criterion are considered
protected.
2.3.3. Acute toxicity-minimal motor impairment
To assess a compound’s undesirable side effects (toxicity), ani-
mals are monitored for overt signs of impaired neurological or
muscular function. In mice, the rotorod (Dunham and Miya,
1975) procedure is used to disclose minimal muscular (MMI)
or neurological impairment (MNI). When a mouse is placed
on a rod that rotates at a speed of 6 rpm, the animal can main-
tain its equilibrium for long periods of time. The animal is con-
sidered toxic if it falls off this rotating rod three times during a
1 min period. In addition to MMI, animals may exhibit a
circular or zigzag gait, abnormal body posture and spread of
the legs, tremors, hyperactivity, lack of exploratory behavior,
somnolence, stupor, catalepsy, loss of placing response and
changes in muscle tone.
3. Results and discussion
3.1. Chemistry
The chemical structures of the synthesized compounds were
conﬁrmed by infrared spectroscopy, proton nuclear magnetic
resonance spectroscopy, mass spectrometry, and elemental
analysis. The presence of carbonyl and oleﬁnic groups in com-
pound 1 is characterized by the presence of two strong bands
in its IR spectrum at 1732 and 1522 cm1. The formations of
compound 2 were conﬁrmed by the appearance of singlet peak
3.12 for two protons in its 1H NMR spectra which might be
assigned to the NH group connecting the pyrimidine. The con-
version of thiazolo[3,2-a]pyrimidin-3(7H)-one (3) can be recog-
nized by a strong absorption peak at 1641 cm1 in IR due to
the carbonyl group in the thiazole ring. The title compounds
(4a-i) showed a singlet at d 7.09, 7.12, 7.31, 7.34, 7.36, 7.29,
7.21, 7.27 and 7.23 ppm due to the benzylidine ring in 1H
NMR that conﬁrms the formation of (4a–i) respectively. Fur-
ther mass spectra conﬁrmed their purity and molecular weight.
3.2. Antiepileptic activity
The antiepileptic activity of the synthesized compounds was
investigated for all representative compounds (4a–i) by MESand scPTZ. Compounds found to be active in these seizure
challenges are generally regarded to be signiﬁcantly useful
candidates in the treatment of partial, generalized and even
the absence of seizures. The data regarding the antiepileptic
screening of all the compounds are reported in Table 1.
In both electroshock and chemoshock investigations, three
compounds 4f, 4g and 4h were found to be signiﬁcantly active
as they showed protection at the lowest dose of 30 mg/kg after
0.5 h. These compounds continued to show the activity after
4.0 h but at higher doses (100 mg/kg). It emerged as themost ac-
tive antiepileptic agent and it is equally potent when compared
with the reference standards Phenytoin and Ethosuximide. The
promising nature of the compounds may be attributed due to
the substitutions at the hydrophobic domain. These compounds
had electron withdrawing groups at the para position of the
hydrophobic aryl ring. The higher dose required for a longer
duration of activity may be because of the high lipophilicity
of the compounds as it results in bidirectional movements of
the compounds through the blood–brain barrier. Among all
the compounds, 4f was found to be remarkably active at 30–
100 mg/kg dose after 0.5 h and 4.0 h in both MES and scPTZ
model. The other compounds 4a, 4d and 4e except 4b, 4c and
4i showed considerable antiepileptic activity. It was observed
that in this method, the most active compounds have substitu-
tion at the para position of the distal aryl ring by electron with-
drawing groups resulting in increased antiepileptic activity. The
reports indicate that 67% of the compounds that are, 4f,4g, 4h,
4a, 4d and 4e showed activity in either MES or scPTZ model at
30 or 100 mg/kg dose after 0.5 h.
3.3. Neurotoxicity screen
The results obtained showed that most of the candidate
compounds exhibited neurotoxicity at doses higher than widely
S6 V. Karthick et al.prescribed drugs Phenytoin or Carbamazepine. But while eval-
uating antiepileptic compounds, separation between antiepilep-
tic and neurotoxic doses is desirable. All the compounds were
evaluated for their neurotoxicity except4b, 4c and 4i due to their
poor responses in antiepileptic activity. In neurotoxic study 4d
was found to be neurotoxic at 100 mg/kg. Compounds 4a, 4e,
4f, 4g and 4h showed neurotoxicity at 300 mg/kg.
3.4. Structure–activity relationships (SAR) analysis
On correlating the structures of the sample candidate with their
biological activities, it has been observed that, out of various
phenyl substituted derivatives, three compounds (4f, 4g and
4h) have signiﬁcance toward both MES and scPTZ activities
(at 30 and 100 mg/kg). The nature of the substituted group on
the phenyl ring appeared to greatly inﬂuence the antiepileptic
activity. On analyzing the antiepileptic activity of all the com-
pounds (4a–i), the following SAR was gained. Presence of hal-
ogens at para position greatly increased antiepileptic activity.
Among halogen analogs ﬂuoro derivatives exhibited better
activity followed by chloro and bromo, whereas the presence
of a methyl substituent showed moderate activity. Methoxy
and nitro derivatives exhibited least activity.
4. Conclusion
From Table 1, it is clear that the synthesized title compounds
(4f–h) showed signiﬁcant antiepileptic activity. The fact is that
a majority of clinically active antiepileptics possess a nitrogen
hetero atomic system with one or two phenyl rings, at least one
carbonyl group in their structure and presence of a hydrogen
bonding site. The synthesized compounds’ structures satisﬁed
all the pharmacophoric structural requirements that is, the
presence of a substituted aryl moiety as the hydrophobic por-
tion, N and O as electron donor systems, the presence of a car-
bonyl group and another hydrophobic distal chlorophenyl ring
responsible for controlling the pharmacokinetic properties of
the antiepileptics. To conﬁrm this suggestion, further studies
are now in progress based on molecular modeling.Acknowledgments
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